Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €5.62 EUR
Change Today -0.04 / -0.71%
Volume 16.6K
As of 3:35 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

epigenomics ag (ECX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/23/15 - €6.92
52 Week Low
10/14/14 - €2.79
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EPIGENOMICS AG (ECX)

Related News

No related news articles were found.

epigenomics ag (ECX) Related Businessweek News

No Related Businessweek News Found

epigenomics ag (ECX) Details

Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic tests for the screening, early detection, and diagnosis of cancer in Germany. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer, which relies on its proprietary DNA methylation biomarker, Septin9. The company also offers Epi proLung BL Reflex Assay, a confirmatory test that aids in the diagnosis of lung cancer. Its development pipeline also contains tests for screening, monitoring, diagnosis, and prognosis assessment in colorectal, lung, and prostate cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

37 Employees
Last Reported Date: 05/12/15
Founded in 1998

epigenomics ag (ECX) Top Compensated Officers

Chief Executive Officer, Chief Financial Offi...
Total Annual Compensation: €377.3K
Chief Operating Officer and Member of Executi...
Total Annual Compensation: €300.0K
Compensation as of Fiscal Year 2014.

epigenomics ag (ECX) Key Developments

Epigenomics AG Announces Earnings Results for the First Quarter Ended March 31, 2015

Epigenomics AG announced earnings results for the first quarter ended March 31, 2015. For the quarter, the company revenue slightly decreased to EUR 367,000 compared to EUR 407,000 for the same period last year. LBIT was EUR 3.2 million compared to EUR 2.0 million for the same period last year and net loss for the period to EUR 3.2 million compared to EUR 2.2 million for the same period last year. Due to the increased number of shares outstanding at the end of first quarter of 2015, net loss per share increased only slightly to EUR 0.20 compared to EUR 0.17 for the same period last year. Cash outflow from operating activities was EUR 2.2 million compared to EUR 1.5 million for the same period last year which was mainly attributable to the ADMIT trial and to building up product inventory for expected product demand in the months to come.

Epigenomics AG - Shareholder/Analyst Call

Epigenomics AG - Shareholder/Analyst Call

Epigenomics AG Presents at BioEquity Europe 2015, May-20-2015 09:00 AM

Epigenomics AG Presents at BioEquity Europe 2015, May-20-2015 09:00 AM. Venue: InterContinental Vienna, Vienna, Austria.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ECX:GR €5.62 EUR -0.04

ECX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ECX.
View Industry Companies

Industry Analysis


Industry Average

Valuation ECX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPIGENOMICS AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at